Arsenic Trioxide-Induced Death of Neuroblastoma Cells Involves Activation of Bax and Does Not Require p53

Clinical Cancer Research

Volumn 10, Issue 9, 2004, Pages 3179-3188

  Karlsson, Jenny ^a   Øra, Ingrid ^a,b   Pörn Ares, Isabella ^a   Påhlman, Sven ^a,c  

^a Department of Laboratory Medicine ^*  (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c MAS   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC TRIOXIDE; CALPAIN; CARBOPLATIN; CASPASE 3; CYTOCHROME C; DOXORUBICIN; ETOPOSIDE; PROTEIN BAX; PROTEIN P21; PROTEIN P53; VINCRISTINE;

APOPTOSIS; ARTICLE; CELL DEATH; CELL FRACTIONATION; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; MITOCHONDRION; MULTIDRUG RESISTANCE; NEUROBLASTOMA; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; ARSENICALS; BCL-2-ASSOCIATED X PROTEIN; BLOTTING, WESTERN; CALPAIN; CARBOPLATIN; CASPASE 3; CASPASES; CELL LINE, TUMOR; CYTOCHROMES C; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; ETOPOSIDE; HUMANS; MUTATION; NEUROBLASTOMA; OXIDES; PROTO-ONCOGENE PROTEINS C-BCL-2; TIME FACTORS; TUMOR SUPPRESSOR PROTEIN P53; VINCRISTINE;

EID: 2442583335     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-03-0309     Document Type: Article

References (57)

1. Philip T, Ladenstein R, Lasset C, et al. 1070 myeloablative megatherapy procedures followed by stem cell rescue for neuroblastoma: 17 years of European experience and conclusions. European Group for Blood and Marrow Transplant Registry Solid Tumour Working Party. Eur J Cancer 1997;33:2130-5.
2. Keshelava N, Seeger RC, Groshen S, Reynolds CP. Drug resistance patterns of human neuroblastoma cell lines derived from patients at different phases of therapy. Cancer Res 1998;58:5396-405.
3. Tweddle DA, Malcolm AJ, Bown N, Pearson AD, Lunec J. Evidence for the development of p53 mutations after cytotoxic therapy in a neuroblastoma cell line. Cancer Res 2001;61:8-13.
4. Keshelava N, Zuo JJ, Chen P, et al. Loss of p53 function confers high-level multidrug resistance in neuroblastoma cell lines. Cancer Res 2001;61:6185-93.
5. Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med 1999;341:1165-73.
6. Matthay KK, Castleberry RP. Treatment of advanced neuroblastoma: the US experience. In: Brodeur GM, Sawada T, Tsuchida Y, Voûte PA, editors. Neuroblastoma. Edition 1. Amsterdam: Elsevier; 2000. p. 417-36.
7. Hartmann O, Berthold F. Treatment of advanced neuroblastoma: the European experience. In: Brodeur GM, Sawada T, Tsuchida Y, Voûte PA, editors. Neuroblastoma. Edition 1. Amsterdam: Elsevier; 2000. p. 437-52.
8. Tsuchida Y, Kaneko Y. Treatment of advanced neuroblastoma: the Japanese experience. In: Brodeur GM, Sawada T, Tsuchida Y, Voûte PA, editors. Neuroblastoma. Amsterdam: Elsevier; 2000. p. 453-9.
9. Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993;74:957-67.
10. Lowe SW, Lin AW. Apoptosis in cancer. Carcinogenesis (Lond) 2000;21:485-95.
11. Johnstone RW, Ruefli AA, Lowe SW. Apoptosis: a link between cancer genetics and chemotherapy. Cell 2002;108:153-64.
12. Tinwell H, Stephens SC, Ashby J. Arsenite as the probable active species in the human carcinogenicity of arsenic: mouse micronucleus assays on Na and K arsenite, orpiment, and Fowler's solution. Environ Health Perspect 1991;95:205-10.
13. Wintrobe MM. Clinical Hematology. Edition 5. Philadelphia: Lea & Febinger; 1961.
14. Sun HD, Ma L, Hu XC, Zhang TD. Ai-Lin I treated 32 cases of acute promyeloic leukemia. Chin J Integrat Chin West Med 1992;12:170-1.
15. Soignet SL, Maslak P, Wang ZG, et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 1998;339:1341-8.
16. Jing Y, Dai J, Chalmers-Redman RM, Tatton WG, Waxman S. Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway. Blood 1999;94:2102-11.
17. Larochette N, Decaudin D, Jacotot E, et al. Arsenite induces apoptosis via a direct effect on the mitochondrial permeability transition pore. Exp Cell Res 1999;249:413-21.
18. Costantini P, Chernyak BV, Petronilli V, Bernardi P. Modulation of the mitochondrial permeability transition pore by pyridine nucleotides and dithiol oxidation at two separate sites. J Biol Chem 1996;271:6746-51.
19. Kroemer G, de The H. Arsenic trioxide, a novel mitochondriotoxic anticancer agent? J Natl Cancer Inst (Bethesda) 1999;91:743-5.
20. Kroemer G, Reed JC. Mitochondrial control of cell death. Nat Med 2000;6:513-9.
21. 3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR α/PML proteins. Blood 1996;88:1052-61.
22. Kitamura K, Minami Y, Yamamoto K, et al. Involvement of CD95-independent caspase 8 activation in arsenic trioxide-induced apoptosis. Leukemia (Baltimore) 2000;14:1743-50.
23. Dai J, Weinberg RS, Waxman S, Jing Y. Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system. Blood 1999;93:268-77.
24. Miller WH Jr, Schipper HM, Lee JS, Singer J, Waxman S. Mechanisms of action of arsenic trioxide. Cancer Res 2002;62:3893-903.
25. Akao Y, Nakagawa Y, Akiyama K. Arsenic trioxide induces apoptosis in neuroblastoma cell lines through the activation of caspase 3 in vitro. FEBS Lett 1999;455:59-62.
26. Øra I, Bondesson L, Jonsson C, et al. Arsenic trioxide inhibits neuroblastoma growth in vivo and promotes apoptotic cell death in vitro. Biochem Biophys Res Commun 2000;277:179-85.
27. Vandesompele J, Edsjö A, De Preter K, et al. ID2 expression in neuroblastoma does not correlate to MYCN levels and lacks prognostic value. Oncogene 2003;22:456-60.
28. Biedler JL, Roffler-Tarlov S, Schachner M, Freedman LS. Multiple neurotransmitter synthesis by human neuroblastoma cell lines and clones. Cancer Res 1978;38:3751-7.
29. Biedler JL, Helson L, Spengler BA. Morphology and growth, tumorigenicity, and cytogenetics of human neuroblastoma cells in continuous culture. Cancer Res 1973;33:2643-52.
30. Tumilowicz JJ, Nichols WW, Cholon JJ, Greene AE. Definition of a continuous human cell line derived from neuroblastoma. Cancer Res 1970;30:2110-8.
31. Seeger RC, Rayner SA, Banerjee A, et al. Morphology, growth, chromosomal pattern and fibrinolytic activity of two new human neuroblastoma cell lines. Cancer Res 1977;37:1364-71.
32. Davidoff AM, Pence JC, Shorter NA, Iglehart JD, Marks JR. Expression of p53 in human neuroblastoma- and neuroepithelioma-derived cell lines. Oncogene 1992;7:127-33.
33. Relling MV, Mahmoud HH, Pui CH, et al. Etoposide achieves potentially cytotoxic concentrations in CSF of children with acute lymphoblastic leukemia. J Clin Oncol 1996;14:399-404.
34. Riccardi R, Riccardi A, Lasorella A, et al. Clinical pharmacokinetics of carboplatin in children. Cancer Chemother Pharmacol 1994;33:477-83.
35. Frost BM, Eksborg S, Björk O, et al. Pharmacokinetics of doxorubicin in children with acute lymphoblastic leukemia: multi-institutional collaborative study. Med Pediatr Oncol 2002;38:329-37.
36. Gidding CE, Meeuwsen-de Boer GJ, Koopmans P, et al. Vincristine pharmacokinetics after repetitive dosing in children. Cancer Chemother Pharmacol 1999;44:203-9.
37. Ahn YH, Koh JY, Hong SH. Protein synthesis-dependent but Bcl-2-independent cytochrome C release in zinc depletion-induced neuronal apoptosis. J Neurosci Res 2000;61:508-14.
38. Xiang J, Chao DT, Korsmeyer SJ. BAX-induced cell death may not require interleukin 1 β-converting enzyme-like proteases. Proc Natl Acad Sci USA 1996;93:14559-63.
39. Miller TM, Moulder KL, Knudson CM, et al. Bax deletion further orders the cell death pathway in cerebellar granule cells and suggests a caspase-independent pathway to cell death. J Cell Biol 1997;139:205-17.
40. Quignon F, De Bels F, Koken M, et al. PML induces a novel caspase-independent death process. Nat Genet 1998;20:259-65.
41. Carre M, Carles G, Andre N, et al. Involvement of microtubules and mitochondria in the antagonism of arsenic trioxide on paclitaxel-induced apoptosis. Biochem Pharmacol 2002;63:1831-42.
42. Gross A, Yin XM, Wang K, et al. Caspase cleaved BID targets mitochondria and is required for cytochrome c release, while BCL-XL prevents this release but not tumor necrosis factor-R1/Fas death. J Biol Chem 1999;274:1156-63.
43. Teitz T, Wei T, Valentine MB, et al. Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. Nat Med 2000;6:529-35.
44. Hopkins-Donaldson S, Bodmer JL, Bourloud KB, et al. Loss of caspase-8 expression in highly malignant human neuroblastoma cells correlates with resistance to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Cancer Res 2000;60:4315-9.
45. Mandic A, Viktorsson K, Strandberg L, et al. Calpain-mediated Bid cleavage and calpain-independent Bak modulation: two separate pathways in cisplatin-induced apoptosis. Mol Cell Biol 2002;22:3003-13.
46. Gao G, Dou QP. N-terminal cleavage of bax by calpain generates a potent proapoptotic 18-kDa fragment that promotes bcl-2-independent cytochrome C release and apoptotic cell death. J Cell Biochem 2000;80:53-72.
47. Wood DE, Newcomb EW. Cleavage of Bax enhances its cell death function. Exp Cell Res 2000;256:375-82.
48. Wood DE, Thomas A, Devi LA, et al. Bax cleavage is mediated by calpain during drug-induced apoptosis. Oncogene 1998;17:1069-78.
49. Blomgren K, Zhu C, Wang X, et al. Synergistic activation of caspase-3 by m-calpain after neonatal hypoxia-ischemia: a mechanism of "pathological apoptosis"? J Biol Chem 2001;276:10191-8.
50. Waterhouse NJ, Finucane DM, Green DR, et al. Calpain activation is upstream of caspases in radiation-induced apoptosis. Cell Death Differ 1998;5:1051-61.
51. Cregan SP, Fortin A, MacLaurin JG, et al. Apoptosis-inducing factor is involved in the regulation of caspase-independent neuronal cell death. J Cell Biol 2002;158:507-17.
52. Gross A, Jockel J, Wei MC, Korsmeyer SJ. Enforced dimerization of BAX results in its translocation, mitochondrial dysfunction and apoptosis. EMBO J 1998;17:3878-85.
53. Zhang L, Yu J, Park BH, Kinzler KW, Vogelstein B. Role of BAX in the apoptotic response to anticancer agents. Science (Wash DC) 2000;290:989-92.
54. Wei MC, Zong WX, Cheng EH, et al. Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science (Wash DC) 2001;292:727-30.
55. Ikemoto H, Tani E, Ozaki I, Kitagawa H, Arita N. Calphostin C-mediated translocation and integration of Bax into mitochondria induces cytochrome c release before mitochondrial dysfunction. Cell Death Differ 2000;7:511-20.
56. Lambert C, Apel K, Biesalski HK, Frank J. 2-Methoxyestradiol induces caspase-independent, mitochondria-centered apoptosis in DS-sarcoma cells. Int J Cancer 2004;108:493-501.
57. Wallace-Brodeur RR, Lowe SW. Clinical implications of p53 mutations. Cell Mol Life Sci 1999;55:64-75.